Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-30 vs Thyrogen in Differentiated Thyroid Carcinoma Patients Post-Thyroidectomy
NCT03276988Phase 2Completed
- Sponsor
- Genexine
- Start
- Sep 2017
- Primary completion
- Jan 2020
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GX-30 in differentiated thyroid carcinoma (DTC) (2 arms), sponsored by Genexine. Primary endpoint: Efficacy at Day 4. Started Sep 2017; status: completed.
02
Drugs
GX-30
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT03276988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276988.